Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 14Neoplasms 10Thoracic Neoplasms 3Carcinoma 3Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Neoplasms, Nerve Tissue 2Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2NSCLC 2Meningeal Carcinomatosis 2Lung Diseases 2Colorectal Neoplasms 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Brain Neoplasms 2Adenocarcinoma 2Solid Tumor, Adult 1Renal Insufficiency 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Noonan Syndrome 1Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) 1Multiple Endocrine Neoplasia Type 2a 1Mesothelioma, Malignant 1Lung Cancer Metastatic 1Lethal Congenital Contracture Syndrome 2 1Hemangioendothelioma, Epithelioid 1Head and Neck Neoplasms 1

Interventions

Fluorouracil 71pembrolizumab 62Bevacizumab 60Oxaliplatin 59Cetuximab 59Leucovorin 56Irinotecan 55Capecitabine 31Nivolumab 23Gemcitabine 18Cisplatin 18IFL protocol 17Folfox protocol 17Cyclophosphamide 16Carboplatin 15atezolizumab 14Specimen Handling 14Paclitaxel 14Magnetic Resonance Spectroscopy 14Biopsy 14trifluridine tipiracil drug combination 12Pemetrexed 10spartalizumab 9regorafenib 9fludarabine 9Panitumumab 9130-nm albumin-bound paclitaxel 9trametinib 8durvalumab 8dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Colorectal Neoplasms × osimertinib × Clear all
NCT05647122 2026-05-11

EGRET

AstraZeneca

Phase 1 Recruiting
403 enrolled
GastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasms, Colorectal Neoplasms

NCT05954871 2025-11-13

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

Genentech, Inc.

Phase 1 Completed
10 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡